Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials

European Journal of Cancer

Volumn 42, Issue 7, 2006, Pages 827-834

  Trumper, M ^a   Ross, P J ^a   Cunningham, D ^a   Norman, A R ^a   Hawkins, R ^b   Seymour, M ^c   Harper, P ^d   Iveson, T ^e   Nicolson, M ^f   Hickish, T ^g  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^f ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^g ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Elderly; Oesphago gastric

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN C;

ADVANCED CANCER; AGED; AGING; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELDERLY CARE; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; GROUPS BY AGE; HAND FOOT AND MOUTH DISEASE; HEALTH STATUS; HUMAN; INCIDENCE; INFECTION; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH CANCER; STOMATITIS; SYMPTOM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 33646196614     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.08.044     Document Type: Article

References (23)

1. Statistics NCfH: Leading causes of death and numbers of deaths, according to age: United States, 1980 and 2001 (updated on 1/5/2004); 2004. Available from: http://www.cdc.gov/nchs/data/hus/tables/2003/03hus032.pdf.
2. Statistics NCfH: Chartbook on Trends in Health of Americans, Health United States. US Departmen of Health and and Human Services, Centers for Disease Control and Prevention; 2003. p. 17-88.
3. The Population, The State of the Health in the European Community in 2000. Brussels, European Union; 2000. p. 2-12.
4. Yanick R., and Ries L. Aging and cancer in America: demographic and epidemiologic perspectives. Haematol Oncol Clin North Am 14 (2000) 17-23
5. Glimelius B., Ekstrom K., Hoffman K., et al. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8 (1997) 163-168
6. Pyrhonen S., Kuitunen T., Nyandoto P., et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71 (1995) 587-591
7. Murad A., Santiago F., Petroianu A., et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72 (1993) 37-41
8. Lewis J., Kilgore M., Goldman D., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21 (2003) 1383-1389
9. Hutchins L., Unger J., Crowley J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 (1999) 2061-2067
10. Popescu R., Norman A., Ross P., et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17 (1999) 2412-2418
11. Folprecht G., Cunningham D., Ross P., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15 (2004) 1330-1338
12. Chau I., Norman A., Cunningham D., et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer (2004)
13. Chau I., Norman A., Cunningham D., et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomised, controlled trials using individual patient data. J Clin Oncol 22 (2004) 2395-2403
14. Louvet C., Carrat F., Mal F., et al. Prognostic factor analysis in advanced gastric cancer patient treated with hydroxyurea, leucovorin, 5-fluorouracil and cisplatin (HLFP regimen). Cancer Invest 21 (2003) 14-20
15. Polee M., Hop W., Kok T., et al. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 89 (2003) 2045-2050
16. Rougier P., Ducreux M., Mahjoubi M., et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer A 30 (1994) 1263-1269
17. Tebbutt N., Norman A., Cunningham D., et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 13 (2002) 1568-1575
18. Ross P., Nicolson M., Cunningham D., et al. Prospective randomised trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20 (2002) 1994-2004
19. Webb A., Cunningham D., Scarffe H., et al. Randomised trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15 (1997) 261-267
20. Chau I., Norman A., Cunningham D., et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan. Br J Cancer 91 (2004) 1453-1458
21. Sargent D., Goldberg R., Jacobson S., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345 (2001) 1091-1097
22. Jacobson S., Cha S., Sargent D., et al. Tolerability, dose intensity, and benefit of 5FU-based chemotherapy for Advanced Colorectal Cancer (CRC) in the elderly. A North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 20 (2001) 1534 [abstract]
23. Cassidy J., Twelves C., Van Cutsem E., et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13 (2002) 566-575